MPX INTERNATIONAL ANNOUNCES THAT ITS MALTA SUBSIDIARY, ALPHAFARMA OPERATIONS LTD., RECEIVES ITS MEDICAL CANNABIS LICENSE

­­­­­NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.


MPX INTERNATIONAL ANNOUNCES THAT ITS MALTA SUBSIDIARY, ALPHAFARMA OPERATIONS LTD., RECEIVES ITS MEDICAL CANNABIS LICENSE

TORONTO, ONTARIO, April 20, 2022 – MPX International Corporation (“MPX International”, “MPXI” or the “Corporation”) (CSE:MPXI; OTC:MPXOF), a multinational diversified cannabis company, is pleased to announce that its Maltese indirect subsidiary, Alphafarma Operations Ltd. (“Alphafarma”) has received its License for the Production of Cannabis for Medicinal and Research Purposes (the “Medical Cannabis License”) issued by the Malta Medicines Authority.  This follows the attainment of the European Union Good Manufacturing Practice certification (the “EU-GMP Certification”) issued by the Medicines Authority of Malta in January 2022.  

The receipt of the Medical Cannabis License is the final requirement for Alphafarma to begin commercial production and export of finished medical cannabis flower products from Malta into markets across Europe and elsewhere.

Alphafarma has already secured EU GMP sourced material from licensed cultivation partners.  This will be supplemented with additional cannabis flower from its South African-based EU-GMP First Growth cultivation facility, likely in late 2023. 

The first product has already been successfully registered in Malta, and it will be launched for distribution under MPXI’s own Salus BioPharma brand in Q3 2022.  Similar entry into other markets such as Germany, Czech Republic, Poland and New Zealand are expected later on in the year.  

Through this licensing process, MPXI has become one of the very few companies with an EU-GMP Certified and fully licensed cannabis facility which is actually located in the European marketplace. In line with its expansion plans, Alphafarma has already started working towards applying for a license amendment to process cannabis derivatives, such as oils.

“The Medical Cannabis License is a significant milestone for MPXI’s operations in Europe and MPXI’s international growth strategy. Our team in Malta has been exceptional in its pursuit of the License and is well positioned for the next phase which is the export of cannabis flower” said W. Scott Boyes, Chairman, President and CEO of MPXI. “This achievement reinforces our plans to create a global cannabis company.  MPXI is uniquely positioned to be the only cannabis company with revenue generating operations in North America, Europe and Asia, which MPXI believes will lead to additional strategic opportunities.”

Karl Bartolo, General Manager and Director of Alphafarma said “We are extremely proud of our team in Malta for this incredible achievement, especially through the challenging circumstances presented by the pandemic.  We will continue working relentlessly on introducing new technologies and formulations in order to provide patients and prescribers consistent access to a wide portfolio of medical cannabis products of the highest quality, safety and efficacy standards.”  

About MPX International Corporation

MPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across the international cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient. With current operations spanning four continents in Canada, Switzerland, South Africa, Malta, Australia and Thailand as well as evolving partnership and distribution opportunities in other jurisdictions, MPXI continues to position itself as an emergent global participant in the cannabis industry. 

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; the Corporation’s ability to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic; future cannabis pricing; cannabis cultivation yields; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel and contracted relationships with third parties; the regulatory environment in Australia, Canada, Malta, South Africa, Switzerland, Thailand  and other international jurisdictions; the ability to complete any future potential transactions and the terms and conditions thereof; the application of federal, state, provincial, county and municipal laws; and the impact of increasing competition; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com, including its audited annual consolidated financial statements for the financial years ended September 30, 2021 and 2020, and the corresponding management’s discussion and analysis; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information about MPXI, please contact:

MPX International Corporation

  1. Scott Boyes, Chairman, President and CEO

T: +1-416-840-4703
E: info@mpxinternationalcorp.com

 

or visit one our websites:

https://mpxinternationalcorp.com

https://strainrec.ca

https://cbdetc.com

https://canveda.ca

https://holyworld.ch/en

https://miracbd.ca

https://spartannetwork.ca

http://mpxi.tv

https://network.mothersmary.com

https://www.high12brands.com

http://www.saluseurope.com

https://salusbioceutical.co.th